Details up front: 98.2% · Janoshik · 99.4%.
Before I write this off, I want to check whether it is a known failure mode.
I have the lot number, the certificate and the date, and I am happy to compare them against anything.
What is the most likely explanation, and how would I confirm it?
1.2 percentage points, and the direction is the informative half. Janoshik reports 98.2 per cent and the certificate 99.4, so the independent figure is lower. As impurity that is 1.8 per cent against 0.6 — 3 times as much unassigned area. A gentler gradient resolves impurities that a steeper one hides beneath the main peak, so the better method routinely reports the worse number; 1.2 points is comfortably inside what method choice alone produces on identical material. Ask both parties for the method section before you decide which figure is wrong, because the answer is often neither.
The honest answer is that the achievable range of plausible purity figures for a given vial is wider than most people expect.
Gradient slope controls resolution, and gentler slopes resolve co-eluting impurities into separate peaks — so the better method reports the worse purity number.
| Test | Answers | Does NOT answer |
|---|---|---|
| RP-HPLC, area % | What fraction of detected material is the target | How much target is present |
| Quantified content | Milligrams of peptide per vial | What the impurities are |
| ESI-MS identity | Whether the molecular weight matches | Purity, or isomeric substitution |
| Peptide mapping | Sequence, localised to a fragment | Quantity |
| Karl Fischer | Water content of the solid | Solvent content |
| LAL endotoxin | Pyrogen load in EU/mg | Sterility |
| Sterility test | Growth in defined media over 14 days | Endotoxin, or bioburden count |
Mobile phase additive choice affects ionisation and peak shape — TFA gives sharp peaks but suppresses mass spectrometry signal, formic acid gives worse peaks but preserves signal.
Inter-laboratory studies on identical peptide material routinely find half-a-per-cent to a full-per-cent spreads in reported purity on the same sample.
The practical summary: ask for the chromatogram and the method, and ignore the headline number until you have both.
Aggregated, published test results and vendor ratings built from submitted batches. Methodology stated, dataset browsable, no listing fees.
Browse resultsOn the detail: reporting threshold is convention and not chemistry, which is why two certificates with different thresholds disagree by a tenth of a point or more.
The fraction of your main peak that is actually your target versus isomers, fragments or related sequences is invisible without complementary identity testing.
Mass on column affects detector linearity and peak overlap — overloading broadens peaks and hides neighbours, while underloading improves resolution but loses sensitivity.
The ICH Q3A impurity thresholds and the relevant pharmacopoeial chapters all specify method validation requirements that almost no research-grade certificate claims to meet.
Compare purity within a single laboratory on the same method, never across laboratories.
The method matters more than the vial, which is why specifying a method buys you far more than changing suppliers does.
Sample solvent strength affects peak shape — if you inject in strong solvent on a gradient starting in weak solvent, the solvent peak can distort your main peak or create a false shoulder.
Column pore size affects mass transfer — a 100 Angstrom packing on a 5 kDa peptide restricts diffusion, broadening the peak and potentially hiding small impurities in the shoulders.
Published side-by-side method comparisons show that a two-point difference in purity on the same vial is easily explained by method choice alone.
If you are ranking vendors, specify a method and have all samples tested at the same place.
The part that matters: identity and purity are orthogonal, and a high purity says almost nothing about whether the peak is actually what you think it is.
Detection wavelength matters because 214 nm sees the peptide backbone while 280 nm sees only aromatic side chains — so truncation impurities lacking a tryptophan are invisible at 280 nm.
The caveat is that purity without identity is only half an answer — a high purity does not mean the peak is actually what you think it is.
If you only pay for one test, pay for quantified content. Purity is the number everyone quotes and content is the number that changes what you do.
Understanding purity requires separating the chemistry from the method from the reporting convention, and the three are not independent.
Retention time is sequence-specific and method-specific, so comparing your result to a supplier value using a different method is meaningless without method documentation.
I would be careful about over-reading a single measurement — treat it as a data point, not as ground truth.
In practice: ask for the chromatogram, check the method section, check the lot number against the vial, and set your accept threshold before you see the result rather than after.
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.